drugset

drugset / Trial / NCT00323869

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

NCT00323869 ↗

Phase 2 Completed 48 enrolled Stanford University Eli Lilly and Company · collab Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

A multi-center study of bevacizumab in combination with gemcitabine and carboplatin as treatment for newly-diagnosed advanced non-small cell lung cancer (NSCLC).

Timeline

Start: 2006-06
Primary completion: 2013-10
Completion: 2013-10

Publications

Results Clement-Duchene C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oncol. 2010 Nov;5(11):1821-5. doi: 10.1097/JTO.0b013e3181f1d23c.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Gemcitabine	Small molecule	1000 mg/m2	Intravenous

Indications